Therefore, PNA-mediated targeting of miR-335-5p in Calu-3 cells is expected to lead, in addition to the up-regulation of NHERF1 and CFTR (Figure 4), to the down-regulation of IL-8, possibly combining two activities of great interest in CF therapy, i.e., CFTR potentiation and anti-inflammatory effects. Here, NHERF1 is linked to cystic fibrosis.